Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
Head-to-head comparison of Hydrafinil (9-Fluorenol) and Modafiendz — mechanism, dosing, side effects, legal status, and pricing.
Hydrafinil (9-fluorenol) is a non-peptide fluorene derivative and secondary benzylic alcohol (C₁₃H₁₀O, MW 182.22) investigated as a potential wakefulness-promoting agent structurally distinct from modafinil's diphenylmethyl-sulfinyl scaffold. It has no approved human indication and is not FDA-approved or approved by any regulatory body for human or veterinary use. Hydrafinil is listed as an S6.A Non-Specified Stimulant on the WADA Prohibited List; Section S6.A stimulants are prohibited in-competition only, so it is banned in-competition and athletes are subject to strict liability. It is sold online by research-chemical vendors for laboratory use only, not for human consumption.
Modafiendz is a non-peptide diphenylmethylsulfinylacetamide, specifically an N-methylated, bis(4-fluoro)-ring-substituted analog of modafinil. It is an unapproved research/designer chemical with no marketing authorization in any jurisdiction and no validated human dose. Its closest structural relatives, flmodafinil (CRL-40,940) and fladrafinil (CRL-40,941), are explicitly named as WADA-prohibited S6 stimulants on the 2026 list; Modafiendz itself is not explicitly named but may fall under WADA's generic “similar structure or effect” clause. No human pharmacokinetic, safety, or efficacy studies have been published.
Hydrafinil (9-Fluorenol)
Modafiendz
Category
Legal Status
Mechanism
Dose Range
Route
COA-verified vendors · trust score ≥70 required · single-vial price — bulk/bundle deals may be lower
Hydrafinil (9-Fluorenol)
No pricing data yet.
Check Hydrafinil (9-Fluorenol) prices →Modafiendz
No pricing data yet.
Check Modafiendz prices →COA corpus from Disclosed Labs — independently tested batches only.
Hydrafinil (9-Fluorenol)
2
COAs
99.0%
Avg purity
1
Labs
Modafiendz
2
COAs
99.5%
Avg purity
2
Labs
No human efficacy or safety trials have been conducted. The only human data is a 2021 pilot pharmacokinetic/analytical study (Knoop et al., PMID 34378339) in which three healthy male volunteers received a single 50 mg oral dose of hydrafinil, with urine collected up to 72 hours post-dose to characterize Phase I/II metabolites (hydroxylated, glucuronidated, sulfo-conjugated) for anti-doping detection purposes; this study was designed solely for metabolite identification and does not establish safety, efficacy, or a validated dose. In rats, a Cephalon Inc. drug-discovery program screened fluorene-derived compounds as candidate next-generation modafinil agents; one analog ('compound 15') showed wake-promoting activity attributed to an active metabolite ('compound 3'), though the published abstract does not confirm compound 3's identity as fluorenol or provide potency data.
No human data exists. No ClinicalTrials.gov record, no DrugBank entry, and no INN was found; NCATS Inxight Drugs classifies it only as “Other (designer drug),” racemic, with no approval year. Only two PubMed-indexed publications reference this compound, both analytical/forensic chemistry papers: one validated an LC-HRMS method to screen dietary supplements for modafinil analogs (adrafinil, not Modafiendz, was confirmed present in tested products), and one analyzed heat-induced thermal degradation during GC-MS (relevant to forensic identification). No preclinical pharmacology, toxicology, or efficacy studies in animals have been published.
Key references
Hydrafinil (9-Fluorenol) and Modafiendz are both in the Cognitive category and may have overlapping mechanisms. Researchers should review both profiles carefully, understand the mechanisms of action, and monitor the relevant biomarkers when combining compounds in the same class. As always, consult a licensed healthcare provider before making any decisions about combining research compounds.
This platform provides informational tools only, not medical advice. This comparison is for educational purposes only. Consult a licensed provider.
Frequency
Dosing Notes
Side Effects
Contraindications
Lab Testing
Disclosed Labs